Analysis | Metabolite Name | Measured Value | Units | Drug combination | 13C-label position in pyruvate |
---|---|---|---|---|---|
ESI/QTOF negative ion mode | Erythrose 4-phosphate | 5070.096 | Peak area | Isoproterenol + Leelamine | C2 |
ESI/QTOF negative ion mode | Erythrose 4-phosphate | 9190.372 | Peak area | Isoproterenol | C1 |
ESI/QTOF negative ion mode | Erythrose 4-phosphate | 11220.39 | Peak area | Rosiglitazone + Leelamine | C2 |
ESI/QTOF negative ion mode | Erythrose 4-phosphate | 16045.67 | Peak area | Isoproterenol | C2 |
ESI/QTOF negative ion mode | Erythrose 4-phosphate | 21333.66 | Peak area | None | C2 |
ESI/QTOF negative ion mode | Erythrose 4-phosphate | 21652.28 | Peak area | Rosiglitazone | C1 |
ESI/QTOF negative ion mode | Erythrose 4-phosphate | 22705.71 | Peak area | None | C1 |
ESI/QTOF negative ion mode | Erythrose 4-phosphate | 23562.5 | Peak area | Rosiglitazone | C2 |
ESI/QTOF negative ion mode | Erythrose 4-phosphate | Peak area | Isoproterenol + Leelamine | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate | Peak area | Rosiglitazone + Leelamine | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_1 | Peak area | Isoproterenol | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_1 | Peak area | Isoproterenol | C2 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_1 | Peak area | Isoproterenol + Leelamine | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_1 | Peak area | Isoproterenol + Leelamine | C2 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_1 | Peak area | None | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_1 | Peak area | None | C2 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_1 | Peak area | Rosiglitazone | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_1 | Peak area | Rosiglitazone | C2 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_1 | Peak area | Rosiglitazone + Leelamine | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_1 | Peak area | Rosiglitazone + Leelamine | C2 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_2 | Peak area | Isoproterenol | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_2 | Peak area | Isoproterenol | C2 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_2 | Peak area | Isoproterenol + Leelamine | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_2 | Peak area | Isoproterenol + Leelamine | C2 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_2 | Peak area | None | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_2 | Peak area | None | C2 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_2 | Peak area | Rosiglitazone | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_2 | Peak area | Rosiglitazone | C2 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_2 | Peak area | Rosiglitazone + Leelamine | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_2 | Peak area | Rosiglitazone + Leelamine | C2 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_3 | 7.58416 | Peak area | Rosiglitazone | C1 |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_3 | 12.02762 | Peak area | Rosiglitazone | C2 |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_3 | Peak area | Isoproterenol | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_3 | Peak area | Isoproterenol | C2 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_3 | Peak area | Isoproterenol + Leelamine | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_3 | Peak area | Isoproterenol + Leelamine | C2 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_3 | Peak area | None | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_3 | Peak area | None | C2 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_3 | Peak area | Rosiglitazone + Leelamine | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_3 | Peak area | Rosiglitazone + Leelamine | C2 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_4 | 232.149 | Peak area | Rosiglitazone | C1 |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_4 | Peak area | Isoproterenol | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_4 | Peak area | Isoproterenol | C2 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_4 | Peak area | Isoproterenol + Leelamine | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_4 | Peak area | Isoproterenol + Leelamine | C2 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_4 | Peak area | None | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_4 | Peak area | None | C2 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_4 | Peak area | Rosiglitazone | C2 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_4 | Peak area | Rosiglitazone + Leelamine | C1 | |
ESI/QTOF negative ion mode | Erythrose 4-phosphate_13C_4 | Peak area | Rosiglitazone + Leelamine | C2 |